The maximal effect of inhaled ipratropium occurs 30–60 minutes after use; its duration of action is 3 to 6 hours and bronchodilation can usually be maintained with treatment 3 times a day.

Ipratropium is a bronchodilator that is used to to prevent bronchospasm in people with COPD (chronic obstructive pulmonary disease), including bronchitis and emphysema. Ipratropium inhalation may also be used for purposes not listed in this medication guide.

Ipratropium bromide is a white crystalline substance, freely soluble in water and lower alcohols. It is a quaternary ammonium compound and thus exists in an ionized state in aqueous solutions. It is relatively insoluble in non-polar media. Ipratropium Bromide Inhalation Solution is administered by oral inhalation with the aid of a nebulizer.

Ipratropium bromide, sold under the trade name Atrovent among others, is a medication which opens up the medium and large airways in the lungs. It is used to treat the symptoms of chronic obstructive pulmonary disease and asthma. It is used by inhaler or nebulizer. Onset of action is typically within 15 to 30 minutes and lasts for three to five hours.

Ipratropium belongs to the group of medicines known as antimuscarinic bronchodilators. It is given to improve the airflow to your lungs. It works by opening up the air passages in your lungs so that air can flow into your lungs more freely.

Ipratropium is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease – COPD which includes bronchitis and…

Ipratropium bromide inhaler (Atrovent, Atrovent HFA) is a medication prescribed for the treatment of allergic or nonallergic rhinitis and rhinitis due to the common cold. Oral ipratropium is prescribed for the treatment of acute asthma flares and bronchospasms that result from COPD (chronic obstructive pulmonary disease) and emphysema.

Ipratropium Accession Number DB00332 Description. Ipratropium is a quaternary ammonium derivative of atropine 4 that acts as an anticholinergic agent. 1 It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. 4. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy …